Significant biosimilar activities this week include 24 Feb 20 | The FDA launched a searchable version of the 'Purple...
Pearce IP BioBlast™: w/e 28 February 2020
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Emily Dwyer
Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management.
A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.
See Emily's full profile
Pfizer announces hestitance to launch Amsparity in EU
Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch...
Harbour BioMed receives FDA approval of Investigational New Drug application
On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an...
Pearce IP BioBlast™: w/e 21 February 2020
Significant biosimilar activities this week include 12 Feb 20 | Wockhardt announced divestment of assets to Dr...
BioPharma Reporter reports AbbVie defence strategy for Humira
On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab)...
Pearce IP BioBlast™: f/e 07 February 2020
Significant biosimilar activities this fortnight include 05 Feb 20 | Merck announced a new spin-off company which will...
Pearce IP BioBlast™: w/e 24 January 2020
Significant biosimilar activities this week include Jan 20 | Genentech and Roche commenced recruitment for Ph III...